IsoRay’s Cesium-131 Selected by Chicago Prostate Cancer Center for Use in the Launch of a Study of the Focal Treatment of Prostate Cancer

IsoRay’s Cesium-131 Picked by Chicago Prostate Cancer cells Center for Usage in the Launch of a Study of the Focal Therapy …

12:36 GMT

Cesium-131 Usage in Prostate Focal Cancer Treatment Intends to Reduce Negative effects and Improve Patient High quality of Life RICHLAND, WA–(Marketwired – Jun 29, 2015) – IsoRay, Inc. (NYSE MKT: ISR), a clinical technology firm and innovator in brachytherapy as well as medical isotope applications, today announced that Dr. Brian J. Moran, Supervisor of Chicago Prostate Cancer cells Facility in Westmont, … (continue checking out)